SEC Form 4 · accession 0001179110-18-008052
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew A. F. Hack
Officer — Chief Financial Officer
Period of report
Jun 1, 2018
Accepted (ET)
Jun 5, 2018 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2018 | M | 5,000 | $6.48 | A | 5,000 | D | |
| Common StockF2 | Jun 1, 2018 | S | 5,000 | $39.05 | D | 0 | D | |
| Common Stock | Jun 1, 2018 | M | 2,000 | $6.48 | A | 2,000 | D | |
| Common StockF3 | Jun 1, 2018 | S | 2,000 | $39.86 | D | 0 | D | |
| Common Stock | Jun 4, 2018 | M | 3,000 | $24.60 | A | 3,000 | D | |
| Common Stock | Jun 4, 2018 | S | 3,000 | $37.10 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $6.48 | Jun 1, 2018 | M | 7,000 | D | — | Sep 13, 2025 | Common Stock | 7,000 | 41,513 | D |
| Stock Option (right to buy)F5 | $24.60 | Jun 4, 2018 | M | 3,000 | D | — | Feb 28, 2027 | Common Stock | 3,000 | 67,500 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 30, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $38.6 to $39.57. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $39.6 to $40.17. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.
- F5This option was granted on March 1, 2017 and is scheduled to vest over four years in equal monthly installments beginning on March 1, 2017 through March 1, 2021.